RO6870810 + atezolizumab

RO6870810 + atezolizumab is an experimental combination therapy consisting of the small molecule bromodomain and extra-terminal domain (BET) inhibitor RO6870810 and the monoclonal antibody checkpoint inhibitor atezolizumab. RO6870810 acts as an epigenetic modulator by inhibiting BET proteins, leading to transcriptional repression of oncogenic pathways. Preclinical studies suggest that BET inhibition may attenuate the PD-1/PD-L1 immune checkpoint axis, providing a rationale for combining it with immunomodulatory agents such as atezolizumab. Atezolizumab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), thereby blocking its interaction with PD-1 and B7.1 receptors on T cells to enhance antitumor immune responses. This combination was investigated in a Phase 1b clinical trial for advanced ovarian cancer and triple-negative breast cancer (TNBC). The study was terminated early due to increased incidence of immune-related adverse effects without evidence of synergistic antitumor activity[1][2][5].

Other names

BET inhibitor RO6870810 + PD-L1 antibody atezolizumab